Dr Klaassen is a pediatric hematologist and leads the Comprehensive Hemophilia Care Clinic at CHEO. A full professor in the Department of Pediatrics at the University of Ottawa with a certificate in epidemiology, he is also the sitting president of the Association of Hemophilia Clinic Directors of Canada (AHCDC) Well known as both a clinician and researcher in health related Quality of Life, Dr Klaassen is the owner/inventor of the Transfusion Quality of Life measure (TranQol) for thalassemia patients, Kid’s ITP tools and the QUALMS (myelodysplastic syndrome). National and international collaborations are ongoing for academic research on immune thrombocytopenia (ITP) and marrow failure and his team actively participates in a number of registered clinical trials.
Successful treatment of pediatric primary hepatic Burkitt lymphoma using rituximab: A case report
Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H-FIT)
The H-FIT has good preliminary measurement properties and may be responsive to changes in therapy associated with a decreased burden of administration.
Adverse events in the paediatric emergency department: a prospective cohort study
Conclusion One in 40 children suffered adverse events related to ED care. A high proportion of events were preventable. Management and diagnostic issues warrant further study.
Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013
Through an innovative approach using provincial health administrative, immigration and demographic data, this study identified a rising incidence and prevalence of hemoglobinopathies among Ontario children <18 years of age between April 1, 1991 and March 31, 2013, potentially due to increased immigration rates.
Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation
We reviewed 22 pediatric patients with advanced myelodysplastic syndrome from a single center, diagnosed between January 2000 and December 2015. Of those, eight patients received off-label azacitidine before hematopoietic stem cell transplantation.